Fresh analysis reveals that individuals who stop using popular GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight much more quickly than those who halt traditional lifestyle programs.
Published data in a prominent health publication demonstrates that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals using these treatments need to be cognizant of the danger of fast weight regain when the medication is stopped," warns researcher Dr. Susan Jebb.
This pace of recovery implies a return to starting mass in about 18 months.
Weighing Therapies
The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers note that individuals who lose weight through diet and exercise generally experience a more gradual creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Doctors propose the mechanism of the drugs accounts for the accelerated rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of the hormone levels far above than normal may cause the body to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making excessive eating much more probable."
A Lifelong Condition?
The NHS suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, considering the likelihood of weight regain, the therapy might need to be long-term.
This perspective is echoed by pharmaceutical companies, who note that the findings "emphasize the persistent character of excess weight," comparing it to managing diseases like diabetes.
User Experiences
Users who have come off the jabs describe a sudden resurgence of hunger.
"It felt as if a trigger activating and I was suddenly extremely hungry," said a patient.
This challenge is exacerbated if individuals have not developed sustainable lifestyle or habit changes during therapy.
Significant Interest
Figures indicate that millions of people in the UK have used these injections in the past year, with desire continuing to grow.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while the jabs are powerful tools for shedding pounds, they are not a standalone solution and maintained weight loss relies on combined behavioural support.
